- Prev close
- $168.10
- Day range
- $166.74 – $169.35
- Next earnings
- in 38 days
AstraZeneca’s latest move was a modest +0.2% against a flat S&P 500 and a +0.8% Nasdaq 100, while fresh EU support for Enhertu and Klygefa adds a concrete pipeline catalyst. The setup looks well-supported rather than event-risky, though the stock still trades at a premium multiple.
AZN
ASTRAZENECA PLC
As of Sep 22, 2026
82/100
Looks healthyHealth ScoreMove Driver
AZN finished +0.2% while the S&P 500 was -0.0% and the Nasdaq 100 was +0.8%, so the session was broadly in line with the market rather than a distinct stock-specific swing. The main identifiable driver is company news: AstraZeneca received positive opinions from the EMA's CHMP for Enhertu and Klygefa in the European Union, which is a stock-positive pipeline and regulatory update. With no peer move data provided, the clean read is that the move was mainly company-specific and reinforced by a benign market backdrop.
Volatility Check
This looks like normal volatility for a large-cap pharma name, not a sign of business deterioration. Revenue is +8.6% YoY TTM and the latest quarter was +6.4% YoY, while EPS is +25.9% YoY TTM and margins are strong at gross +81.3%, operating +22.8%, and net +17.0%. Valuation is not cheap at PE 24.9 and forward PE 16.9, with a PEG of 2.64 — P/E divided by growth, so investors are paying 2.64× the growth rate — which means good news is partly priced in and can also limit upside. Beta is 1.39, so the stock should move more than a low-volatility defensive name, but the current move is still modest relative to that profile.
Earnings Preview
The next earnings date is 2026-10-30. The facts provided do not include analyst consensus revenue or EPS estimates for that print, so I cannot quote expected growth or margins for the upcoming quarter. What the market will likely focus on, based on the current facts, is whether Enhertu and Klygefa convert from positive CHMP opinions into clearer EU commercial impact, whether the latest +6.4% YoY quarterly revenue trend holds, and whether the strong profitability profile — gross +81.3%, operating +22.8%, net +17.0% — remains intact. No prior post-earnings reaction history is provided here, so I won’t infer one.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track AZN with WhyIHold
Get a plain-English explanation the next time ASTRAZENECA PLC makes a big move — so you know whether it's benign or worth your attention.